SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24: 395406.
  • 2
    Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (Stage T2c or lower) prostate cancer. J Urol. 1994; 152: 18501857.
  • 3
    Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994; 152: 18211825.
  • 4
    Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994; 152: 18371842.
  • 5
    Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000; 163: 16321642.
  • 6
    Berry WR., Laszlo J, Cox E, Walker A, Paulson D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer. 1979; 44: 763775.
  • 7
    Mulders PFA, Dijkman GA, Fernandez del Moral P, Theeuwes AGM, Debruyne FMJ. Analysis of prognostic factors in disseminated prostatic cancer. Cancer. 1990; 65: 27582761.
  • 8
    Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in Stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). Semin Oncol. 1994; 21: 613619.
  • 9
    Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer: analysis of two Cancer and Leukemia Group B studies. Clin Cancer Res. 1999; 5: 831837.
  • 10
    Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. Clin Oncol. 2003; 21: 12321237.
  • 11
    Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998; 160: 12201229.
  • 12
    Tu S-M, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet. 2001; 357: 336341.
  • 13
    Petrylak DP, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 15131520.
  • 14
    Tannock IF, Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 15021512.
  • 15
    Crawford ED, Pauler DK, Tangen CM, et al. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): data from Southwest Oncology Group Study S9916 [abstract 4505]. Proc Am Soc Clin Oncol. 2004; 23: 382.
  • 16
    Dahut WL, Gulley JL, Arlen PM, et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 25322539.
  • 17
    Figg WD, Liu Y, Arlen P, et al. A randomized Phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen-independent prostate cancer and bone metastases. J Urol. 2005; 173: 790796.
  • 18
    Figg WD, Dahut W, Duray P, et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001; 8: 18881893.
  • 19
    Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. In: KleinJP, MoeschbergerML, editors. Techniques for censored and truncated data in survival analysis. New York: Springer-Verlag, 1997: 229281.
  • 20
    NeterJ, WassermanW, KutnerM, editors. Simultaneous inferences and other topic in regression analysis-1. In: NeterJ, WassermanW, KutnerM, editors. Applied linear regression models, 1st ed. Homewood, Il: Richard D. Irwin Inc., 1983: 150153.
  • 21
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 22
    Ferro MA, Gillatt D, Symes MO, et al. High dose intravenous estrogen therapy in advanced prostatic carcinoma: use of serum prostate-specific antigen to monitor response. Urology. 1989; 134: 134138.
  • 23
    Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate-specific antigen as a clinical end point for hormone refractory prostatic cancer. J Urol. 1992; 147: 931934.
  • 24
    Smith DC, Dunn RL, Stawderman MS, et al. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 1998; 16: 18351843.
  • 25
    Vollmer RT, Dawson NA, Vogelzang NJ. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate. Cancer. 1998; 83: 19891994.
  • 26
    Scher HI, Kelly WK, Zhang ZF, et al. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst. 1999; 91: 244251.
  • 27
    D'Amico AV, Halabi S, Vogelzang NJ, Small EJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: results of a pooled analysis of CALGB HRPC trials. J Clin Oncol. 2004; 22(14S): 537–556.
  • 28
    Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8: 431440.
  • 29
    Small EJ, McMillan A, Meyer M, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001; 19: 13041311.
  • 30
    Emrich LJ, Priore RL, Murphy GP, et al. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985; 45: 51735179.
  • 31
    Sabbatini P, Larson S, Kremer AB, et al. The prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 948957.
  • 32
    Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in Phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994; 12: 18681875.
  • 33
    Kelly WK, Scher HI, Mazumdar M, et al. Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol. 1993; 11: 607615.
  • 34
    Pienta KJ, Redman BG, Bandekar R, et al. A Phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology. 1997; 50: 401407.